dc.contributor.author | Batirel, Ayşe | |
dc.contributor.author | Balkan, İlker İnanç | |
dc.contributor.author | Karabay, Oğuz | |
dc.contributor.author | Ağalar, Canan | |
dc.contributor.author | Akalın, Şerife | |
dc.contributor.author | Alıcı, Özlem | |
dc.contributor.author | Alp, Emine | |
dc.contributor.author | Altay, Fatma Aybala | |
dc.contributor.author | Altın, Nilgün | |
dc.contributor.author | Arslan, Ferhat | |
dc.contributor.author | Aslan, Turan | |
dc.contributor.author | Bekiroğlu, Nuray | |
dc.contributor.author | Cesur, Salim | |
dc.contributor.author | Çelik, Aygül Dogan | |
dc.contributor.author | Doğan, Mustafa | |
dc.contributor.author | Durdu, Bülent | |
dc.contributor.author | Duygu, Fazilet | |
dc.contributor.author | Engin, Aynur | |
dc.contributor.author | Engin, Derya Öztürk | |
dc.contributor.author | Gönen, İbak | |
dc.contributor.author | Güçlü, Ertuğrul | |
dc.contributor.author | Güven, Tümer | |
dc.contributor.author | Hatipoğlu, Çiğdem Ataman | |
dc.contributor.author | Hoşoğlu, Salih | |
dc.contributor.author | Karahocagil, Mustafa Kasım | |
dc.contributor.author | Ulu Kılıç, Aysegül | |
dc.contributor.author | Örmen, Bahar | |
dc.contributor.author | Özdemir, Davut | |
dc.contributor.author | Özer, Serdar | |
dc.contributor.author | Öztoprak, Nefise | |
dc.contributor.author | Sezak, Nurbanu | |
dc.contributor.author | Turhan, Vedat | |
dc.contributor.author | Türker, Nesrin | |
dc.contributor.author | Yılmaz, Hava | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:52:28Z | |
dc.date.available | 10.07.201910:49:13 | |
dc.date.available | 2019-07-10T19:52:28Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Batirel, A., Balkan, İ. İ., Karabay, O., Ağalar, C., Akalın, Ş., Alıcı, Ö. ... Yılmaz, H. (2014). Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. European Journal of Clinical Microbiology & Infectious Diseases, 33(8), 1311-1322. https://dx.doi.org/10.1007/s10096-014-2070-6 | en_US |
dc.identifier.issn | 0934-9723 | |
dc.identifier.issn | 1435-4373 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s10096-014-2070-6 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/2405 | |
dc.description | 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- 41394 -- Berlin, GERMANY | en_US |
dc.description | WOS: 000338723600006 | en_US |
dc.description | PubMed ID: 24532009 | en_US |
dc.description.abstract | The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Colistin-Carbapenem | en_US |
dc.subject | Colistin-Sulbactam | en_US |
dc.subject | Colistin Plus | en_US |
dc.subject | Antibacterial | en_US |
dc.title | Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections | en_US |
dc.type | article | en_US |
dc.relation.ispartof | European Journal of Clinical Microbiology & Infectious Diseases | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-8554-7651 | en_US |
dc.identifier.volume | 33 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 1311 | en_US |
dc.identifier.endpage | 1322 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s10096-014-2070-6 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q1 | en_US |